Immunology Publications
Clinical Studies
Reduced incidence and severity of acute radiation mucositis by WF10 (IMMUNOKINE) as adjunct to standard of care in the management of head & neck cancer patients. Penpattanagul S. J Med Assoc Thai 2007;90:1590-600.
A phase II study to evaluate WF10 in patients with late hemorrhagic radiation cystitis and proctitis. Veerasarn V, Boonnuch W, Kakanaporn C. Gynecol Oncol 2006;100:179-84.
Reduced recurrence of late hemorrhagic radiation cystitis by WF10 therapy in cervical cancer patients: a multicenter, randomized, two-arm, open-label trial. Veerasarn V, Khorprasert C, Lorvidhaya V, Sangruchi S, Tantivatana T, Narkwong L, et al. Radiother Oncol 2004;73:179-85.
The efficacy of chemically-stabilized chlorite-matrix (TCDO) in the management of late postradiation cystitis. Srisupundit S, Kraiphibul P, Linasmita V, Chingskol K, Veerasarn V. J Med Assoc Thai 1999;82:798-802.
Randomized, double-blind, placebo-controlled trial of the immune modulator WF10 in patients with advanced AIDS. Raffanti SP, Schaffner W, Blackwell RB, Ching OA, Kuhne FW. Infection 1998;26:202-7.
Long-term Survival of a Stage D Prostate Cancer. Kuhne HH, Bressel M, Heitz M, Kuppers F, Loch T, Stockle M. Aktuel Urol 1998;29:261-3.
A double-blind, placebo-controlled, randomized trial to evaluate the role of tetrachlorodecaoxide in the management of chemotherapy-induced oral mucositis.Malik, Moid I, Haq S, Sabih M. J Pain Symptom Manage 1997;14:82-7.
Rationale for and results from a randomised double-blind trial of tetrachlorodecaoxygen anion complex in wound healing. Hinz, H., Hautzinger, H., Stahl, K.W. Lancet 1986; 825-28.
Preclinical Studies in Animals
Immunosuppression in xenotransplantation with WF10. Kemp K, Dieperink H, Hansen A, Johansen A, Jensen J. et al. Pharmacol Toxicol 2002;90:346-8.
High-dose stabilized chlorite matrix WF10 prolongs cardiac xenograft survival in the hamster-to-rat model without inducing ultrastructural or biochemical signs of cardiotoxicity.Hansen A, Kemp K, Kemp E, Bouchelouche K, Bouchelouche P, Dieperink H et al. Pharmacol Toxicol 2001;89:92-5.
WF10 in xenotransplantation-a potential new approach. Kemp E, Dieperink H, Johansen A, Jensen J, Kemp G. et al. Transplant Proc 2000;32:1018-9.
Influence of tetrachlorodecaoxide (Ryoxon) on the development of leukemia after total-body gamma-irradiation. Kempf SR, Blaszkiewitz K, Port RE, Ivankovic S. Oncology 1994;51:510-4.
Anticarcinogenic effect of tetrachlorodecaoxide after total-body gamma irradiation in rats. Kempf SR, Port RE, Ivankovic S. Radiat Res 1994;139:226-31.
Comparative study on the effects of chlorite oxygen reaction product TCDO (tetrachlorodecaoxygen) and sodium chlorite solution (NaClO2) with equimolar chlorite content on bone marrow and peripheral blood of BDIX rats. Kempf SR, Blaszkiewitz K, Reim M, Ivankovic S. Drugs Exp Clin Res 1993;19:165-74.
Stimulation of hematopoietic cell recovery by tetrachlorodecaoxide in sublethally irradiated mice. Mason KA, Murphy S, Milas L. Radiat Res 1993;136:229-35.
The effects of epinephrine, ibuprofen, and tetrachlorodecaoxide on cutaneous microcirculation in thermally injured hamsters. Da Costa R, Aggarwal SJ, Diller KR, Baxter CR. J Burn Care Rehabil 1992;13:396-402.
Effects of tetrachlorodecaoxide (TCDO) in chronic radiation lesions of the rat colon. Sassy T, Breiter N, Trott KR. Strahlenther Onkol 1991;167:191-6.
The Tetrachlorodecaoxygen Complex Reverses the Effect of Cortisone on Wound Healing. Hatz RA, Kelley SF, Ehrlich HP. Plastic Reconstructive Surgery 1989;84:953-9.
Tetrachlorodecaoxygen anion complex treatment after localized X irradiation of the rat colon. Breiter N, Sassy T, Trott KR. Br J Radiol 1989;62:381-3.
Regenerative effects of tetrachlorodecaoxide in BD IX rats after total-body gamma irradiation. Ivankovic S, Kempf SR. Radiat Res 1988;115:115-23.
Preclinical Studies in vitro
Differential effects on innate versus adaptive immune responses by WF10.Giese T, McGrath MS, Stumm S, Schempp H, Elstner E, Meuer SC. Cell Immunol 2004;229:149-58.
Development of WF10, a novel macrophage-regulating agent. McGrath MS, Kahn JO and Herndier BG. Curr Opin Investig Drugs 2002;3:365-73.
Balanced macrophage activation hypothesis: a biological model for development of drugs targeted at macrophage functional states. McGrath MS and Kodeljab V. Pathobiology 1999;67:277-81.
Effect of WF10 (TCDO) on antigen presentation. McGrath MS, Benike C, Kuehne FW and Engleman E. Transplantation Proc 1998;30:4200-4.
Inactivation of HIV infectivity by the chlorite-oxygen reaction product tetrachlorodecaoxygen. Ennen J, Werner K, Kuhne FW, Kurth R. AIDS 1993;7:1205-12.
Antimicrobial effects of the tetrachlorodecaoxygen-anion complex on oropharyngeal bacterial flora: an in vitro study. Stoll P, Huber H, Pelz K, Weingart D. Chemotherapy 1993;39:40-7.
Anti-inflammatory properties of a novel wound healing and immunomodulating agent, tetrachlorodecaoxygen complex (TCDO). Tissot M, Roch-Arveiller M, Mathieu J, Giroud JP, Stahl KW. Agents Actions 1990;31:368-74.
Improvement of tumor spheroid oxygenation by tetrachlorodecaoxide. Mueller-Klieser W, Vaupel P. Int J Radiat Oncol Biol Phys 1987;13:49-54.
Increased resistance towards two systemic experimental infections by tetrachlorodecaoxygen anion complex. Possible implications of cellular and humoral immunity. Gillissen G, Kuhne FW, Breuer-Werle M, Melzer B, Ostendorp H. Arzneimittelforschung. 1986;36:1778-82.
Chemistry/Biochemistry
Chlorite-hemoprotein interaction as key role for the pharmacological activity of the chlorite- based drug WF10. Schempp H, Reim M, Dornisch K, Elstner EF. Arzneimittelforschung 2001;51:554-62.
Time kinetics of hemoglobin and myoglobin activation by tetrachlorodecaoxide (TCDO). Youngman, R.J., Wagner, G.,Kühne, F.W., Elstner, E.F. Free Rad Res Comms 1986; 1; 5; 311-19.
Biochemical oxygen activation as the basis for the physiological action of tetrachlorodecaoxide (TCDO). Youngman, R.J., Wagner, G., Kühne, F.W., Elstner, E.F. Zeitschr. Naturforsch.1985; (40c) 409-14
